Spyglass Pharma (SGP) Stock Price, News & Analysis

Company Overview

SpyGlass Pharma, Inc. is a clinical-stage ophthalmic pharmaceutical company focused on developing long-acting treatments for chronic eye diseases. The company is developing drug-delivery technologies intended to reduce the need for patients to administer topical eye drops regularly.

Its lead development program, SGP-310, is an intraocular implant designed to provide sustained delivery of travoprost, a prostaglandin analog used to lower elevated intraocular pressure. The product is being developed for patients with primary open-angle glaucoma or ocular hypertension, conditions that can increase the risk of vision loss if left untreated.

SpyGlass Pharma’s platform is intended to support extended drug release inside the eye, potentially improving treatment consistency and adherence compared with daily topical medications. The company is headquartered in Irvine, California, and its activities are primarily focused on ophthalmic drug development and clinical research. Further information about its commercial operations and geographic reach is limited because the company remains in the development stage.

Key Stats

• Today's Range: $27.56 to $28.75
• 50-Day Range: $19.52 to $28.99
• 52-Week Range: $17.06 to $32.44
• Volume: 130,173 shs
• Average Volume: 79,612 shs
• Market Capitalization: $958.19 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $44.00
• Consensus Rating: Moderate Buy

Spyglass Pharma Stock Analysis - MarketRank™

Spyglass Pharma scored higher than 46% of companies evaluated by MarketBeat, and ranked 589th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Spyglass Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.63, and is based on no strong buy ratings, 6 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Spyglass Pharma has a consensus price target of $44.00, representing about 53.5% upside from its current price of $28.66.

Amount of Analyst Coverage

Spyglass Pharma has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Spyglass Pharma are expected to decrease in the coming year, from ($2.55) to ($2.83) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Spyglass Pharma is -4.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Spyglass Pharma is -4.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

3.28% of the float of Spyglass Pharma has been sold short.

Short Interest Ratio / Days to Cover

Spyglass Pharma has a short interest ratio ("days to cover") of 15.77, which indicates bearish sentiment.

Change versus previous month

Short interest in Spyglass Pharma has recently decreased by 3.51%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Spyglass Pharma does not currently pay a dividend.

Dividend Growth

Spyglass Pharma does not have a long track record of dividend growth.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.93

News Sentiment

Spyglass Pharma has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Spyglass Pharma this week, compared to 2 articles on an average week.

Search Interest

3 people have searched for SGP on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Spyglass Pharma insiders have not sold or bought any company stock.

Percentage Held by Institutions

Spyglass Pharma has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 9/15/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:SGP
• CIK: 1778922
• Web: www.spyglasspharma.com
• Phone: (949) 284-6904
• Fax: N/A
• Employees: 65
• Year Founded: 2019

Price Target and Rating

• Average Price Target for Spyglass Pharma: $44.00
• High Price Target: $62.00
• Low Price Target: $37.00
• Potential Upside/Downside: +53.5%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.63
• Research Coverage: 8 Analysts

Profitability

• EPS (Trailing Twelve Months): ($7.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$39.87 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -62.40%
• Return on Assets: -24.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 25.06
• Quick Ratio: 25.06

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 33,433,000
• Free Float: N/A
• Market Cap: $958.19 million
• Optionable: N/A
• Beta: N/A